Description

Newron Pharmaceuticals S.p.A. is a biopharmaceutical company in the clinical development phase, focused on discovering and advancing novel therapeutic solutions for central and peripheral nervous system disorders, as well as pain management. Its operations are concentrated in Italy and the United States. The company currently markets Xadago (safinamide) for Parkinson's disease and is further developing it to address levodopa-induced dyskinesia. Its developmental pipeline also includes Evenamide, targeting schizophrenia and its treatment-resistant variants, along with Ralfinamide, an orphan drug candidate for neuropathic pain. Established in 1999, Newron Pharmaceuticals S.p.A. maintains its headquarters in Bresso, Italy.